Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

This study has been terminated.
(Low accrual)
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00609739
First received: February 6, 2008
Last updated: January 31, 2012
Last verified: January 2012

February 6, 2008
January 31, 2012
June 1999
June 2010   (final data collection date for primary outcome measure)
Disease-free Survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Number of patients who were free of disease and alive at 1 year.
1-year disease-free survival [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00609739 on ClinicalTrials.gov Archive Site
  • Patients With Regimen-Related Toxicity [ Time Frame: Up to 30 Days Post Study Treatment ] [ Designated as safety issue: Yes ]
    Number of patients with adverse events related to treatment.
  • Patients With Graft-Versus-Host-Disease [ Time Frame: Up to 30 Days Post Study Treatment ] [ Designated as safety issue: No ]
    Number of patients who exhibited acute and/or chronic graft-versus-host disease.
  • Patients Who Relapsed [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
    Number of patients whose disease relapsed.
  • Incidence of regimen-related toxicity [ Designated as safety issue: Yes ]
  • Incidence of acute and chronic graft-versus-host-disease [ Designated as safety issue: Yes ]
  • Incidence of relapse [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

RATIONALE: Giving chemotherapy drugs, such as cytarabine and mitoxantrone, before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When certain stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, methotrexate, and methylprednisolone before or after transplant may stop this from happening.

PURPOSE: This phase I/II trial is studying the side effects and best way to give high-dose cytarabine together with mitoxantrone in treating patients with juvenile myelomonocytic leukemia undergoing a second donor stem cell transplant.

OBJECTIVES:

Primary

  • To determine the incidence of 1-year disease-free survival in patients with juvenile myelomonocytic leukemia and who is undergoing a repeat stem cell transplantation.

Secondary

  • To evaluate the incidence of regimen-related toxicity.
  • To evaluate the incidence of acute and chronic graft-versus-host-disease.
  • To evaluate the incidence of relapse.

OUTLINE:

  • Preparative cytoreductive therapy: Patients receive high-dose cytarabine IV over 2 hours on days -9 to -4 and mitoxantrone hydrochloride IV over 30 minutes on days -9 to -7.
  • Allogeneic hematopoietic stem cell transplantation (HSCT): Patients undergo HSCT on day 0. Patients undergoing umbilical cord blood transplantation receive methylprednisolone (as graft failure prophylaxis) IV twice daily on days 5 to 19 followed by a taper every other day thereafter until day 25.
  • Graft-versus-host-disease (GVHD) prophylaxis: Patients receive cyclosporine IV over 2 hours every 8-12 hours or orally twice daily beginning on day -3 and continuing until day 50, followed by a taper to day 90, in the absence of GVHD. Patients undergoing nongenotypically identical bone marrow transplantation also receive methotrexate IV on day 1 beginning 24 hours after completion of stem cell infusion and on days 3, 6, and 11.
  • Post-transplantation isotretinoin therapy: Patients receive oral isotretinoin once daily beginning on day 60 and continuing until 1 year after HSCT.

Patients undergo bone marrow sample collection on day 21, day 60, day 100, at 6 months, and at 1 year for chimerism studies. Patients also undergo blood sample collection periodically to monitor peripheral blood counts for immune reconstitution.

After completion of study treatment, patients are followed on day 21, day 100, at 6 months, and at 1 year.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Leukemia
  • Drug: cyclosporine
    Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients >40 kg with normal renal function (creatinine <1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
    Other Name: CSA
  • Drug: cytarabine
    3000 mg/m^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m^2/day) on days -9 through -4.
    Other Name: Ara-C
  • Drug: filgrastim
    Patients with absolute neutrophil count (ANC) <0.2 x 10^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
    Other Name: G-CSF
  • Drug: methotrexate
    MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m^2 IV on days +3, +6, and +11.
    Other Name: MTX
  • Drug: methylprednisolone
    Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
    Other Name: Medrol
  • Drug: mitoxantrone hydrochloride
    10 mg/m^2 over 30 minutes intravenously (IV) on days -9 through -7.
    Other Name: Mitoxantrone
  • Procedure: allogeneic bone marrow transplantation
    Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 >10^8/kg recipient weight. Infused on Day 0.
  • Procedure: umbilical cord blood transplantation
    Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
  • Drug: Cis-Retinoic acid
    Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
    Other Name: isotretinoin
Experimental: Cytarabine + Mitoxantrone
This is a phase I-II study designed to evaluate the efficacy of the administration of high dose cytosine arabinoside and mitoxantrone followed by HCT in patients with JMML who have residual disease or have relapsed after initial HCT.
Interventions:
  • Drug: cyclosporine
  • Drug: cytarabine
  • Drug: filgrastim
  • Drug: methotrexate
  • Drug: methylprednisolone
  • Drug: mitoxantrone hydrochloride
  • Procedure: allogeneic bone marrow transplantation
  • Procedure: umbilical cord blood transplantation
  • Drug: Cis-Retinoic acid
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
1
June 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients age 0-18 with juvenile myelomonocytic leukemia (JMML) who have relapsed or have residual disease after allogeneic HCT. Residual disease is defined as failure to eradicate original disease without prior documentation of remission. Relapse is defined as reappearance of i) leukocytosis with absolute monocytosis >1 x 10^8/L, ii) presence of immature myeloid cells in the peripheral circulation in two consecutive bone marrow specimens taken at least one month apart, or iii) presence of clonal cytogenetic abnormality. The diagnosis of relapse will be supported by the return of an abnormal cytogenetic marker (if present at diagnosis) or the presence of host cells by RFLP or other method.
  • Patients should be at least 6 months from first hematopoietic cell transplant (HCT) if clinically stable. (If JMML is rapidly progressive, second HCT may be performed earlier).

    • Adequate major organ function including:

      • Cardiac: ejection fraction ≥45%
      • Pulmonary: FEV >50%, DLCO >50%
    • Renal: creatinine clearance ≥40 mL/min

      • Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy, ascites)
    • Karnofsky performance status ≥70% or Lansky score ≥50%
  • Written informed consent.

Exclusion Criteria:

  • Active uncontrolled infection within one week of HCT.
Both
up to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00609739
1999LS032, UMN-MT1999-08, 9906M07303
Yes
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Not Provided
Principal Investigator: Margaret L. MacMillan, MD Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP